Tonix Pharmaceuticals Holding Corp has a consensus price target of $4.87 based on the ratings of 3 analysts. The high is $11 issued by Alliance Global Partners on July 22, 2024. The low is $0.6 issued by Noble Capital Markets on April 18, 2022. The 3 most-recent analyst ratings were released by Alliance Global Partners, Dawson James, and Alliance Global Partners on July 22, 2024, February 28, 2024, and August 1, 2023, respectively. With an average price target of $7.33 between Alliance Global Partners, Dawson James, and Alliance Global Partners, there's an implied 3861.82% upside for Tonix Pharmaceuticals Holding Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Tonix Pharmaceuticals (NASDAQ:TNXP) was reported by Alliance Global Partners on July 22, 2024. The analyst firm set a price target for $11.00 expecting TNXP to rise to within 12 months (a possible 5842.73% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ:TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.
There is no last upgrade for Tonix Pharmaceuticals
There is no last downgrade for Tonix Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $6.00 to $11.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.